Avidity Biosciences Stock (NASDAQ:RNA)
Previous Close
$43.25
52W Range
$5.93 - $56.00
50D Avg
$45.27
200D Avg
$34.53
Market Cap
$5.21B
Avg Vol (3M)
$1.30M
Beta
0.91
Div Yield
-
RNA Company Profile
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
RNA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| PLRX | Pliant Therapeutics, Inc. |
| AKRO | Akero Therapeutics, Inc. |
| ARVN | Arvinas, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| MLYS | Mineralys Therapeutics, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| CERE | Cerevel Therapeutics Holdings, Inc. |
| BDTX | Black Diamond Therapeutics, Inc. |
| RLAY | Relay Therapeutics, Inc. |
| BCEL | Atreca, Inc. |
| IGMS | IGM Biosciences, Inc. |
| PASG | Passage Bio, Inc. |
| SWTX | SpringWorks Therapeutics, Inc. |
| PTGX | Protagonist Therapeutics, Inc. |